Indian drugmaker Dr Reddy’s Laboratories hopes to launch a generic version of Novo Nordisk’s blockbuster weight-loss drug ‌Wegovy at a competitive price that could be up to 60% lower than the branded ...

In a significant patent skirmish for the Australian biotech and pharmaceutical sector, AstraZeneca PLC (LSE:AZN, NASDAQ:AZN) has secured a Federal Court ruling that blocks local generics maker ...

CHENNAI: In a discovery that reinforces the footprint of ancient Tamil civilisation across the globe, around 30 inscriptions, the majority of them in Tamil Brahmi, the early Tamil script, have been ...

The findings, which confirm that ancient Tamil traders travelled deep into the Egyptian interior for exploration and tourism, were presented by Swiss scholar Professor Ingo Strauch on the inaugural ...

Zydus and its wholly owned US subsidiary will pay Astellas a total of 120 million dollars under the terms of the agreement disclosed on February 12, 2026. The settlement ends all litigation between ...

Of 30 inscriptions uncovered at the Valley of Kings by Strauch and Schmid, 20 are in Tamil. CHENNAI: Around 2,000 years ago, a Tamil trader who visited the rock-cut tombs of Egyptian pharaohs ...

Unlock the full InfoQ experience by logging in! Stay updated with your favorite authors and topics, engage with content, and download exclusive resources. Ludi Akue discusses how the tech sector’s ...

Oklahomans who purchased certain generic prescription drugs between 2009 and 2019 may be eligible for compensation after two pharmaceutical companies agreed to pay $17.85 million to settle allegations ...

Novartis NOVN-1.46%decrease; red down pointing triangle said it expected a key profitability metric to decline this year in large part due to increased competition in the U.S. from generic drug ...

A monthly overview of things you need to know as an architect or aspiring architect. Unlock the full InfoQ experience by logging in! Stay updated with your favorite authors and topics, engage with ...

Novo Nordisk A/S (NYSE: NVO) is accused of unlawfully extending its monopoly over its diabetes drug Victoza through a multiyear anticompetitive scheme designed to delay generic competition. • What’s ...

Quarter after quarter for the past year, Takeda’s revenues have been bogged down by generic impacts to its stalwart ADHD med Vyvanse. Now that the gap between Vyvanse erosion and growth from new ...